Arrowhead Pharmaceuticals shares are lower on April 2, 2026, with trading action consistent with a financing overhang rather than a fresh clinical headline. The setup is tied to Arrowhead’s recently completed capital raise, which can pressure the stock through incremental share supply and hedging activity associated with convertible notes.

Arrowhead priced concurrent public offerings on January 7, 2026: $625 million aggregate principal amount of 0.00% convertible senior notes due 2032 and 3,100,776 shares of common stock at $64.50 per share (with an alternative of pre-funded warrants for some investors). That structure typically weighs on the stock in subsequent weeks as the market absorbs added float, anticipates potential conversion-related dilution, and reacts to convertible-arbitrage positioning.

With the stock trading below the $64.50 equity-offering price, today’s slide reinforces investor sensitivity to supply/dilution dynamics and the need for a fundamental catalyst to shift attention back to the pipeline and commercialization trajectory. Management has highlighted multiple 2026 pipeline milestones, but until a clear catalyst hits, price action can remain dominated by positioning and technical flows rather than new fundamental updates.